Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2.
Biomed Pharmacother
; 142: 111953, 2021 Oct.
Article
en En
| MEDLINE
| ID: mdl-34343897
Currently, there are over 230 different COVID-19 vaccines under development around the world. At least three decades of scientific development in RNA biology, immunology, structural biology, genetic engineering, chemical modification, and nanoparticle technologies allowed the accelerated development of fully synthetic messenger RNA (mRNA)-based vaccines within less than a year since the first report of a SARS-CoV-2 infection. mRNA-based vaccines have been shown to elicit broadly protective immune responses, with the added advantage of being amenable to rapid and flexible manufacturing processes. This review recapitulates current advances in engineering the first two SARS-CoV-2-spike-encoding nucleoside-modified mRNA vaccines, highlighting the strategies followed to potentiate their effectiveness and safety, thus facilitating an agile response to the current COVID-19 pandemic.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Ingeniería Biomédica
/
Descubrimiento de Drogas
/
Desarrollo de Medicamentos
/
Vacunas contra la COVID-19
/
SARS-CoV-2
/
COVID-19
Límite:
Humans
Idioma:
En
Revista:
Biomed Pharmacother
Año:
2021
Tipo del documento:
Article
País de afiliación:
México
Pais de publicación:
Francia